Get the Stockscreener App
3.28
9.70%
0.29
After Hours:
3.28
Vyne Therapeutics Inc stock is traded at $3.28, with a volume of 192.91K.
It is up +9.70% in the last 24 hours and up +73.54% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$2.99
Open:
$3.01
24h Volume:
192.91K
Relative Volume:
3.00
Market Cap:
$44.10M
Revenue:
$486.00K
Net Income/Loss:
$-28.43M
P/E Ratio:
-0.2971
EPS:
-11.04
Net Cash Flow:
$-26.75M
1W Performance:
+21.93%
1M Performance:
+73.54%
6M Performance:
+25.19%
1Y Performance:
+8.25%
1-Day Range:
$2.96
$3.30
1-Week Range:
$2.57
$3.30
52-Week Range:
$1.57
$4.4808
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate - Simply Wall St
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully - Yahoo Finance
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Shapiro Capital Management LLC Makes New Investment in NCR Voyix Co. (NYSE:VYX) - Defense World
(VYX) Long Term Investment Analysis - Stock Traders Daily
Engine Capital Management LP Purchases Shares of 78,691 NCR Voyix Co. (NYSE:VYX) - MarketBeat
ZIGUP plc Optimistic as Vehicle Supply Improves - TipRanks
ZIGUP plc Optimistic as Vehicle Supply Rises - TipRanks
Wix Is Set for Growth With Expanding Margins and Cash Flow, Analyst Upgrades Stock - Benzinga
What is Voyager Therapeutics Inc (VYGR) Stock Return on Shareholders’ Capital? - SETE News
Wix, GoDaddy in spotlight as Piper Sandler changes ratings on pair - Seeking Alpha
Wix.com (NASDAQ:WIX) Upgraded by Piper Sandler to "Overweight" - MarketBeat
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Xylem Inc. (NYSE:XYL) Shares Sold by Virtu Financial LLC - Defense World
A company insider recently bought 3,648 shares of NCR Voyix Corp [VYX]. Should You Buy? - Knox Daily
HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE reports positive early trial results for inflammation drug - Investing.com
VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202 - TipRanks
VYNE reports positive early trial results for inflammation drug By Investing.com - Investing.com UK
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
VYNE Therapeutics to Participate in September Investor Conferences - StockTitan
VYNE Therapeutics sees cash runway through end of 2025 - TipRanks
VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright - Defense World
VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year - TipRanks
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace
Virtu Financial LLC Takes Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.5% - Defense World
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way? - Simply Wall St
VYNE Therapeutics secures UK patent for inflammation drug - Investing.com
Latest Patent Grant Is Driving VYNE Therapeutics Stock Higher Today - News IMC
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year - Yahoo Finance
VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - StockTitan
How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2% - Yahoo News Malaysia
VYNE Therapeutics Insiders Are Down US$27k But Regain Some Losses - Simply Wall St
VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease - Dermatology Times
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June - Defense World
Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket - Quantisnow
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - StockTitan
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewswire Inc.
VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo News UK
Eventide Asset Management LLC Takes $3.25 Million Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
H.C. Wainwright eyes VYNE stock as Phase 1a trial commences - Investing.com India
H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com Canada
VYNE Therapeutics (NASDAQ:VYNE) Rating Reiterated by HC Wainwright - Defense World
Analyst Scoreboard: 4 Ratings For VYNE TherapeuticsVYNE Therapeutics (NASDAQ:VYNE) - Benzinga
Fostering Mentorship and Support in Early-Stage Physician Assistants - Dermatology Times
VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):